ABAndrea Bonilla-Díaz

Andrea Bonilla-Díaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Bonilla-Díaz has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Ainhoa Larrañaga

    Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain

    1 shared publication
  • Albert Álvarez-Muñoz

    Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain

    1 shared publication
  • Alessia Mira

    Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy

    1 shared publication
  • Anna Esteve-Codina

    Centro Nacional de Analisis Genomico (CNAG)

    1 shared publication
  • Anna Sapino

    INOC - Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Italy

    1 shared publication
  • Carlos Sebastián

    Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    Pdk1-dependent metabolic heterogeneity promotes aggressive colorectal cancer through cell-intrinsic interferon signaling

    by Jessica Calviello, Lisa Pöltl, Alessia Mira, Filippo Spini, Ainhoa Larrañaga, Lídia Fortuny, Federica Vianello, Andrea Bonilla-Díaz, Albert Álvarez-Muñoz, Giulia Pazzagli, et al.

    Tumor heterogeneity is a major determinant of tumor progression and therapeutic resistance, yet the contribution of metabolism to intratumoral heterogeneity still remains poorly explored. Here, we find that pyruvate dehydrogenase kinase-1 (Pdk1) expression defines metabolically distinct cancer cell populations in colorectal tumors. Image-based spatial single-cell phenotyping shows that Pdk1 high cells are associated with tumor progression in orthotopic models of colorectal cancer (CRC). Genetic ablation experiments demonstrate the role of Pdk1 high cells in tumor growth, 5-fluorouracil chemoresistance and tumor relapse. Mechanistically, we identify a link between Pdk1-driven metabolic states and specific cell phenotypes, where Pdk1 high cancer cells exhibit an EMT, stem cell-like phenotype characterized by increased interferon (IFN) signaling. Mitochondrial remodeling in Pdk1 high cells leads to the release of mitochondrial DNA to the cytosol and activation of IFN pathways, promoting Pdk1-driven phenotypes. Inhibition of IFN signaling impairs the tumorigenic and aggressive features of Pdk1 high cancer cells, thus establishing a functional connection between metabolic heterogeneity, cell-intrinsic IFN signaling and aggressive CRC.